- Axsome Therapeutics to Present at Upcoming Investor Conferences
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
- Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
- Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
More ▼
Key statistics
As of last trade Axsome Therapeutics Inc (AXSM:NMQ) traded at 76.94, -21.81% below its 52-week high of 98.40, set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 75.58 |
---|---|
High | 77.03 |
Low | 73.52 |
Bid | 75.00 |
Offer | 77.50 |
Previous close | 76.94 |
Average volume | 608.53k |
---|---|
Shares outstanding | 47.49m |
Free float | 38.36m |
P/E (TTM) | -- |
Market cap | 3.65bn USD |
EPS (TTM) | -6.38 USD |
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.
More ▼